

substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before March 24, 2025. Such persons may also file a written request for a hearing on the application on or before March 24, 2025.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on September 27, 2024, Groff Health Inc., 2218 South Queen Street, York, Pennsylvania 17402-4631 applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Psilocybin .....	7437	I
Psilocyn .....	7438	I

The company plans to bulk manufacture the listed controlled substances for internal use or for sale to its customers. No other activities for these drug codes are authorized for this registration.

**Matthew Strait,**

*Deputy Assistant Administrator.*

[FR Doc. 2025-01349 Filed 1-17-25; 8:45 am]

**BILLING CODE P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-1477]

**Bulk Manufacturer of Controlled Substances Application: Siegfried USA, LLC**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Siegfried USA, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before March 24, 2025. Such persons may also file a written request for a hearing on the application on or before March 24, 2025.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on November 20, 2024, Siegfried USA, LLC, 33 Industrial Park Road, Pennsville, New Jersey 08070-3244 applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid.	2010	I
Dihydromorphine .....	9145	I
Hydromorphanol .....	9301	I
Amphetamine .....	1100	II
Lisdexamfetamine .....	1205	II
Methylphenidate .....	1724	II
Amobarbital .....	2125	II
Pentobarbital .....	2270	II
Secobarbital .....	2315	II

Controlled substance	Drug code	Schedule
Codeine .....	9050	II
Oxycodone .....	9143	II
Hydromorphone .....	9150	II
Hydrocodone .....	9193	II
Methadone .....	9250	II
Methadone intermediate	9254	II
Morphine .....	9300	II
Oripavine .....	9330	II
Thebaine .....	9333	II
Opium tincture .....	9630	II
Oxymorphone .....	9652	II
Tapentadol .....	9780	II

The company plans to bulk manufacture the listed controlled substances in bulk for sale to its customers. No other activities for these drug codes are authorized for this registration.

**Matthew Strait,**

*Deputy Assistant Administrator.*

[FR Doc. 2025-01350 Filed 1-17-25; 8:45 am]

**BILLING CODE P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-1474]

**Bulk Manufacturer of Controlled Substances Application: Invizyne Technologies, Inc.**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Invizyne Technologies, Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before March 24, 2025. Such persons may also file a written request for a hearing on the application on or before March 24, 2025.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be

aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on November 14, 2024, Invizyne Technologies, Inc., 750 Royal Oaks Drive, Suite 106, Monrovia, California 91016–6357 applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Tetrahydrocannabinols ...	7370	I

The company plans to bulk manufacture the listed controlled substance for the internal use intermediates or for sale to its customers. In reference to drug code 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture this drug as synthetic. No other activity for this drug code is authorized for this registration.

**Matthew Strait,**

*Deputy Assistant Administrator.*

[FR Doc. 2025–01347 Filed 1–17–25; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF JUSTICE

### National Institute of Justice

[OJP (NIJ) Docket No. 1833]

#### Body Armor Manufacturer Workshop

**AGENCY:** National Institute of Justice, Office of Justice Programs, U.S. Department of Justice.

**ACTION:** Notice.

**SUMMARY:** The National Institute of Justice (NIJ) will hold an online workshop for body armor manufacturers to provide updates on its standards and conformity assessment activities related to ballistic-resistant body armor.

**DATES:** The workshop will be held online Wednesday, March 19, 2025, from 1 p.m. to 3 p.m. eastern time.

**FOR FURTHER INFORMATION CONTACT:** Jared Gardner, Technology and Standards Advisor, Office of Technology and Standards, National Institute of Justice, 999 North Capitol Street NE, Washington, DC 20531, by telephone at (202) 702–2917 [Note: this is not a toll-free telephone number], or by email at [jared.gardner@usdoj.gov](mailto:jared.gardner@usdoj.gov).

**SUPPLEMENTARY INFORMATION:** The National Institute of Justice (NIJ) will hold an online workshop for body armor manufacturers to provide updates on its standards and conformity assessment activities related to ballistic-resistant body armor. NIJ will discuss recent addenda to NIJ Standard 0101.07, “Ballistic Resistance of Body Armor”, and NIJ Standard 0123.00, “Specification for NIJ Ballistic Protection Levels and Associated Test Threats”. The NIJ Compliance Testing Program (CTP) will update program participants on the initial implementation of testing body armor to NIJ Standard 0101.07 (“07”) and the anticipated timeline for publication of the NIJ Compliant Products List (CPL) for those “07” armor models. The NIJ CTP will also discuss ongoing administration of the NIJ CPL for armor compliant with NIJ Standard 0101.06 (“06”) and continued Follow-up Inspection and Testing (FIT) for those “06” armor models. Potential revisions to NIJ CTP program requirements will also be discussed, including FIT testing procedures for “07” armor models listed on the NIJ CPL, disclosure of information about ballistic materials used to manufacture body armor submitted to the NIJ CTP for certification, and labeling requirements, among others. NIJ will also discuss potential changes to how information is displayed on the NIJ Compliant Products List and how it anticipates future updates to NIJ standards and NIJ CTP program requirements will be communicated.

The workshop will be presented as an online webinar with opportunities for attendees to ask questions. To register for the workshop, please send an email to [askctp@nijctp.org](mailto:askctp@nijctp.org) by 5 p.m. eastern time on Friday, March 14, 2025, and provide the name of your company and the names of the representatives who will attend. Please put “Body Armor Manufacturer Workshop” in the subject line of the email. A preliminary agenda will be sent to registered attendees approximately 48 hours prior to the workshop.

For more information on NIJ’s standards and conformity assessment activities, please visit <https://nij.ojp.gov/topics/equipment-and-technology/standards-and-conformity-assessment>. For more information on body armor, please visit <https://nij.ojp.gov/topics/equipment-and-technology/body-armor>. More information on the NIJ CTP can be found here: <https://cjttec.org/compliance-testing-program/>.

NIJ publishes this notice pursuant to its authority at 34 U.S.C. 10122(c) and 6 U.S.C. 161–165.

**Nancy La Vigne,**

*Director, National Institute of Justice.*

[FR Doc. 2025–01247 Filed 1–17–25; 8:45 am]

**BILLING CODE 4410–18–P**

## DEPARTMENT OF LABOR

### Employee Benefits Security Administration

[Exemption Application No. D–12101]

#### Proposed Exemption From Certain Prohibited Transaction Restrictions Involving Northern Trust Corporation (Together With its Current and Future Affiliates, Northern or the Applicant) Located in Chicago, IL

**AGENCY:** Employee Benefits Security Administration, Labor.

**ACTION:** Notice of proposed exemption.

**SUMMARY:** This document provides notice of the pendency before the Department of Labor (the Department) of a proposed individual exemption from certain prohibited transaction restrictions of the Employee Retirement Income Security Act of 1974 (ERISA) and the Internal Revenue Code of 1986 (the Code). The proposed exemption would allow certain entities with specified relationships to Northern Trust Fiduciary Services (Guernsey) Limited (NTFS) (hereinafter, the Northern QPAMs, as further defined in section I(e) of the operative language) to rely on the exemptive relief provided by Prohibited Transaction Class Exemption 84–14 (PTE 84–14 or the QPAM Exemption), notwithstanding the judgment of conviction (the Conviction) against NTFS for aiding and abetting tax fraud entered in France in the Paris Court of Appeal, French Special Prosecutor No. 1120392066, French Investigative Judge No. JIRSIF/11/12.

**DATES:**

*Exemption date:* This proposed exemption would be in effect for a period of five years beginning on March 5, 2025, and ending on March 4, 2030 (the Exemption Period).

*Comments due:* Written comments and requests for a public hearing on the proposed exemption should be submitted to the Department by March 7, 2025.

**ADDRESSES:** All written comments and requests for a hearing should be submitted to the Employee Benefits Security Administration (EBSA), Office of Exemption Determinations, Attention: Application No. D–12101 via